好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications
Epilepsy/Clinical Neurophysiology (EEG)
P3 - Poster Session 3 (5:00 PM-6:00 PM)
10-008
To retrospectively examine all-cause mortality in patients after initiating cenobamate vs mortality in patients treated with selected antiseizure medications (ASMs) that have similar patterns of use in medication-resistant epilepsy.
A previous post-hoc analysis of survival in a clinical trial cohort showed that the all-cause standardized mortality ratio (SMR) for cenobamate-treated patients was 1.32 (95% CI: 0.84-2.0), which was not significantly different from the general population.
De-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated therapeutic doses of cenobamate or another selected ASM (brivaracetam, clobazam, lacosamide, eslicarbazepine, or perampanel) between 1/1/2020-12/5/2024. New initiations were identified with at least a 1-year washout. Patients were included if they remained on treatment for ≥90 days after initiation. Patients with an epilepsy-related emergency room visit or inpatient admission in the previous 6 months were excluded. Mortality rates were examined for cenobamate and the comparator ASMs with SMRs and Cox proportional hazards. A sensitivity analysis used propensity matching (4:1 ratio) to account for differences in patients who initiated cenobamate.
3184 patients (51.4% female; mean age 44.8 years) were included. In the overall cohort (n=634 cenobamate; n=2550 other ASMs), 4 and 88 deaths occurred in the cenobamate and comparator ASM groups, respectively; in the propensity-matched cohort (n=361 cenobamate, n=1444 other ASMs), 2 and 36 deaths occurred, respectively. Patients who initiated cenobamate had a mortality rate indistinguishable from that of the general population (SMR 0.69, 95% CI: 0.014-1.37). Patients who initiated comparator ASMs had a higher-than-expected mortality rate (SMR 1.97, 95% CI: 1.56-2.39). Cenobamate was associated with a 68% reduction in mortality rate compared to the other ASMs (HR 0.32, 95% CI: 0.12-0.92; P=0.04). Similar findings were observed after propensity matching.
Patients treated with cenobamate at therapeutic doses had lower mortality rates than patients treated with selected comparable ASM.
Authors/Disclosures
Philip Webber, PhD (SK Life Science)
PRESENTER 		Dr. Webber has received personal compensation for serving as an employee of SK Life Science Inc.
Emily Klatte, MD (Ohio Health Neurological Physicians) Dr. Klatte has received personal compensation in the range of $0-$499 for serving as a Consultant for SK Life Science . Dr. Klatte has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis, Inc. Dr. Klatte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis.
Michael R. Sperling, MD, FAAN (Thomas Jefferson University) Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium .
William E. Rosenfeld, MD, FAAN (Comprehensive Epilepsy Care Center for Children and Adults) The institution of Dr. Rosenfeld has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for SK Life Science. Dr. Rosenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for SK Life Science.
Marc Kamin, MD Dr. Kamin has received personal compensation for serving as an employee of SK LIFE SCIENCE INC.
Sean Stern (SK life science) Mr. Stern has received personal compensation for serving as an employee of SK Life Science.
Clarence Wade (SK life science) Clarence Wade has nothing to disclose.
Wesley Kerr, MD, PhD (University of Pittsburgh) Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from 好色先生. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care.